The Quantellect read.As of Nov 19, 2026, 3 active firms cover Silence Therapeutics PLC: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $32.00 to $75.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $53.50 sits 170% above the current $19.82. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$53.50
+169.9% upside
Average target across 2 active firms as of Nov 19, 2026 vs $19.82 current
Highest Target$75.00
Average Target$53.50
Lowest Target$32.00
Detailed analyst forecasts for SLN
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate SLN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SLN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.28 – $-0.11 · 3 analysts · -49% YoY
Next period, 3 analysts expect Silence Therapeutics PLC to earn $-0.17 a share (range $-0.28 – $-0.11), versus $-0.33 a year earlier. Full-year consensus is $-0.37, growing to $-0.38 the year after.
REVENUE · NEXT QUARTER
$83.8K
Range $0 – $335.0K · 3 analysts · -73% YoY
Revenue is expected to reach $83.8K (range $0 – $335.0K), -73.0% year-over-year. Full-year consensus is $314.9K, rising to $865.5K next year.
Top analysts covering Silence Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SLN.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$27.00+36.2% to target
Overall win rate
41%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$75.00+278.4% to target
Overall win rate
36%
+ Follow
#3
MU
Michael Ulz
Morgan Stanley
Buy
$32.00+61.5% to target
Coverage
—
+ Follow
#4
RL
Richard Law CFA
Goldman Sachs
Sell
$4.00-79.8% to target
Coverage
—
+ Follow
#5
RL
Richard Law
Goldman Sachs
Sell
$3.00-84.9% to target
Coverage
—
+ Follow
SLN stock forecast FAQ
What is SLN's average 12-month price target?+
The 2 active firms with a live target average $53.50 for Silence Therapeutics PLC over the next 12 months, ranging from a $75.00 high to a $32.00 low, as of Nov 19, 2026.
Is SLN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SLN?+
The Street-high target is $75.00 (HC Wainwright & Co.), and the Street-low is $32.00 (Morgan Stanley). The average of all 2 active-firm targets is $53.50.
How many active Wall Street firms cover SLN?+
3 active firms have a recognized rating on Silence Therapeutics PLC as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SLN?+
Among analysts who currently cover SLN, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $27.00 target.
What is Silence Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.28 – $-0.11) across 3 analysts. Full-year EPS is projected at $-0.37, rising to $-0.38 the following year.
How much revenue is Silence Therapeutics PLC expected to report next quarter?+
Consensus revenue is $83.8K (range $0 – $335.0K). Full-year revenue is projected at $314.9K, growing to $865.5K next year.
Have analysts been upgrading or downgrading SLN lately?+
As of Nov 19, 2026, 3 of 3 active firms rate SLN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SLN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.